Quick Read Pfizer (PFE) offers a rare combination of a 6.5% dividend yield with a promising pipeline of oncology treatments and a new Lyme disease vaccine, trading at 9.1x forward P/E despite being 55% below its 2021 peak. Patent expirations through 2026 are dragging down revenue expectations, but the company’s Antibody-Drug Conjugate cancer candidates in Phase 2 and 3 trials and its $10 billion oncology revenue goal by 2030 could offset the decline if successful. Have You read The New Report Shaking ...